These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36896952)

  • 1. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
    Caldera F; Spaulding AC; Borah B; Moriarty J; Zhu Y; Hayney MS; Farraye FA
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1326-1334. PubMed ID: 36896952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
    Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
    Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
    Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
    Desai A; Hashash JG; Kochhar GS; Hayney MS; Caldera F; Farraye FA
    J Crohns Colitis; 2024 Jun; 18(6):828-835. PubMed ID: 38224526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
    Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
    Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease.
    Khan N; Wang L; Trivedi C; Pernes T; Patel M; Xie D; Yang YX
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1570-1578.e1. PubMed ID: 34274513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
    Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
    Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults.
    You JHS; Ming WK; Tsang OT; Chan PK
    PLoS One; 2019; 14(1):e0210005. PubMed ID: 30608953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.
    Teng L; Mizukami A; Ng C; Giannelos N; Curran D; Sato T; Lee C; Matsuki T
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1447-1467. PubMed ID: 35668295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
    Kochhar GS; Desai A; Caldera DO F; El Hachem S; Aoun E; Sandhu D; Mohan BP; Dulai PS; Farraye FA
    Vaccine; 2021 Jul; 39(30):4199-4202. PubMed ID: 34140170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
    Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
    CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.